The third VERDI General Assembly meeting took place on 26-27 June 2023, in Ayia Napa, Cyprus, with over 70 participants from 29 centres of excellence within the VERDI Consortium attending the event, both online and in person. This meeting was particularly noteworthy...
VERDI’s Maternal-Infant Working Group: Prioritising pregnant women and their babies in COVID-19 research
VERDI’s Maternal-Infant Working Group aims to understand how different SARS-CoV-2 variants and vaccination against COVID-19 during pregnancy influences multiple health outcomes in both mother and infant. The Maternal-Infant Working Group is also assessing how to maximise available linked pregnancy/infant data across countries in Europe and worldwide.
The aim of VERDI’s Clinical Working Group is to gain a deeper understanding of the effects of COVID-19 on paediatric populations. Combining research efforts from multiple countries, this working group strives to inform clinical decision-making, improve paediatric healthcare practices, and develop targeted prevention, diagnostic, and treatment strategies for children.
The EU-funded END-VOC project is organising the online scientific symposium “COVID-19 variants and the next pandemic”, which will be held on 6 June 2023, 14.00–18.00 CEST.
Ali Judd, VERDI co-scientific coordinator, shares insights on her experience with the VERDI Consortium.
The VERDI Consortium, coordinated by the University of Padua and Fondazione Penta ETS (Italy), has received an additional €5 million funding from the European Union (EU). Thanks to this contribution, VERDI will examine the impact of mpox on populations at higher risk...
We would like to invite hospitals to participate in a study of mpox in children and adolescents globally. This mpox paediatric and adolescent clinical study is a Joint EU Clinical Research Initiative which is part of the VERDI project, in collaboration with...
The second VERDI General Assembly took place from 28-30 June 2022, bringing together more than 70 people both online and in Padua, Italy.
Study reveals moderate effectiveness of Pfizer Covid-19 vaccine against Omicron in children aged 5-11
A large study on the effectiveness of the Pfizer-BioNTech Covid-19 vaccine in children aged 5-11 was published in The New England Journal of Medicine.
On 26-28 January 2022 the VERDI General Assembly Meeting took place – an exciting 3-day online event bringing together experts in infectious diseases from the EU and beyond.